IDT Australia Ltd (IDT) - Financial And Strategic SWOT Analysis Review
Published Date: 24 Oct 2019
Number of Pages: 40
Category: SWOT Analysis
IDT Australia Ltd (IDT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
IDT Australia Ltd (IDT) is a contract manufacturing company that specializes in the development, scale-up and production of active pharmaceutical ingredients (APIs) and finished dosage forms. It undertakes the process of manufacturing from initial drug development to clinical trials. The company provides range of services including chemical, pharmacy, regulatory services, analytical chemistry, project management services and clinical packaging for early phase clinical trials. It provides services to various pharmaceutical companies including Roche, Teva, Bayer, Pfizer and Johnson & Johnson. IDT is headquartered in Boronia, Victoria, Australia.
IDT Australia Ltd Key Recent Developments
Oct 14,2019: IDT Australia: API development agreement to conclude
Sep 04,2019: FDA lifts IDT Australia warning letter
Aug 28,2019: FDA revises IDT’s facility inspection classification
Aug 23,2018: IDT Australia: Preliminary final report for the year ended 30 June 2018
Jul 25,2018: IDT Australia: FDA Meeting Update
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Section 1 - About the Company
IDT Australia Ltd - Key Facts
IDT Australia Ltd - Key Employees
IDT Australia Ltd - Key Employee Biographies
IDT Australia Ltd - Major Products and Services
IDT Australia Ltd - History
IDT Australia Ltd - Company Statement
IDT Australia Ltd - Locations And Subsidiaries
Section 2 – Company Analysis
IDT Australia Ltd - Business Description
IDT Australia Ltd - SWOT Analysis
SWOT Analysis - Overview
IDT Australia Ltd - Strengths
IDT Australia Ltd - Weaknesses
IDT Australia Ltd - Opportunities
IDT Australia Ltd - Threats
IDT Australia Ltd - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Annual Ratios
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
IDT Australia Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
IDT Australia Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
IDT Australia Ltd, Recent Deals Summary
Section 5 – Company’s Recent Developments
Oct 14, 2019: IDT Australia: API development agreement to conclude
Sep 04, 2019: FDA lifts IDT Australia warning letter
Aug 28, 2019: FDA revises IDT’s facility inspection classification
Aug 23, 2018: IDT Australia: Preliminary final report for the year ended 30 June 2018
Jul 25, 2018: IDT Australia: FDA Meeting Update
Jul 02, 2018: IDT Australia Appoints Chief Executive Officer
Jun 22, 2018: FDA Issues Warning Letter to IDT Australia Ltd
Jun 08, 2018: IDT Australia: Update on Response to Fda Warning Letter
Feb 16, 2018: IDT Australia Names Dr David Sparling As Interim Chief Executive Officer
Section 6 – Appendix